ifosfamide has been researched along with Myelodysplastic Syndromes in 7 studies
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Poor-risk solid tumors were treated with four courses of cyclophosphamide (4,200 mg/m2)/ doxorubicin (75 mg/m2), and three courses of ifosfamide (9,000 mg/m2)/etoposide (500 mg/m2)." | 2.69 | High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. ( Bajorin, D; Cheung, NK; Heller, G; Kramer, K; Kushner, BH; Meyers, PA; Polyak, T; Wollner, N, 1998) |
| " Primary therapies were divided into four groups: radiotherapy alone, moderately dosed COPP/ABVD-like chemotherapies for intermediate and advanced stages and BEACOPP escalated." | 1.37 | Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. ( Diehl, V; Engert, A; Franklin, J; Hasenclever, D; Josting, A; Loeffler, M; Scholz, M, 2011) |
| "One patient developed a secondary acute myeloid leukemia (s-AML) involving a chromosomal translocation t(11;19)(q23;p13." | 1.33 | Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. ( Boehlke, I; Bokemeyer, C; Hartmann, JT; Kanz, L; Kollmannsberger, C; Kuczyk, M; Metzner, B; Schleicher, J; Schleucher, N; Wierecky, J, 2005) |
| "The interval between diagnosis of Ewing's sarcoma and the diagnosis of the SM was 17-78 months for the four AMLs, 96 months for the MDS and 82-136 months for the three sarcomas." | 1.30 | Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. ( Ahrens, S; Dunst, J; Harms, D; Jürgens, H; Paulussen, M; Rübe, C; Winkelmann, W; Zoubek, A, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scholz, M | 1 |
| Engert, A | 1 |
| Franklin, J | 1 |
| Josting, A | 1 |
| Diehl, V | 1 |
| Hasenclever, D | 1 |
| Loeffler, M | 1 |
| Kawakami, K | 1 |
| Watanabe, Y | 1 |
| Kadowaki, S | 1 |
| Christodoulou, J | 1 |
| Schoch, C | 1 |
| Schnittger, S | 1 |
| Haferlach, T | 1 |
| Wierecky, J | 1 |
| Kollmannsberger, C | 1 |
| Boehlke, I | 1 |
| Kuczyk, M | 1 |
| Schleicher, J | 1 |
| Schleucher, N | 1 |
| Metzner, B | 1 |
| Kanz, L | 1 |
| Hartmann, JT | 1 |
| Bokemeyer, C | 1 |
| Takizawa, A | 1 |
| Miura, T | 1 |
| Fujinami, K | 1 |
| Osada, Y | 1 |
| Tanaka, M | 1 |
| Maruta, I | 1 |
| Kushner, BH | 1 |
| Heller, G | 1 |
| Cheung, NK | 1 |
| Wollner, N | 1 |
| Kramer, K | 1 |
| Bajorin, D | 1 |
| Polyak, T | 1 |
| Meyers, PA | 1 |
| Dunst, J | 1 |
| Ahrens, S | 1 |
| Paulussen, M | 1 |
| Rübe, C | 1 |
| Winkelmann, W | 1 |
| Zoubek, A | 1 |
| Harms, D | 1 |
| Jürgens, H | 1 |
1 trial available for ifosfamide and Myelodysplastic Syndromes
| Article | Year |
|---|---|
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dose-Res | 1998 |
6 other studies available for ifosfamide and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine | 2011 |
[Therapy-related acute myelogenous leukemia (AML-M6) with add(11) (q23) and del(20) (q11.2) developing via myelodysplastic syndrome after chemotherapy for malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; | 2003 |
Myelodysplastic syndrome (RARS) with +i(12p) abnormality in a patient 10 months after diagnosis and successful treatment of a mediastinal germ cell tumor (MGCT).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 12; Cisplatin; Etopo | 2004 |
Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Etopo | 2005 |
[A case of therapy-related leukemia/myelodysplastic syndrome following treatment of refractory testicular germ cell tumor].
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Ci | 2005 |
Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 1998 |